The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Radiosensitization of androgen receptor (AR)-positive triple-negative breast cancer (TNBC) cells using seviteronel (SEVI), a selective CYP17 lyase and AR inhibitor.
 
Corey Wayne Speers
Patents, Royalties, Other Intellectual Property - PFS Genomics
 
Benjamin Chandler
No Relationships to Disclose
 
Shuang Zhao
No Relationships to Disclose
 
Meilan Liu
No Relationships to Disclose
 
Kari Wilder-Romans
No Relationships to Disclose
 
Eric Olsen
No Relationships to Disclose
 
Shyam Nyati
No Relationships to Disclose
 
James M. Rae
No Relationships to Disclose
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Honoraria - Lilly
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Travel, Accommodations, Expenses - Janssen Diagnostics
 
Daniel Eidelberg Spratt
No Relationships to Disclose
 
Daniel Richard Wahl
No Relationships to Disclose
 
Felix Yi-Chung Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Consulting or Advisory Role - Celgene; GenomeDx; Medivation/Astellas
Research Funding - Celgene; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Lori J. Pierce
Stock and Other Ownership Interests - PFS Genomics
Patents, Royalties, Other Intellectual Property - PFS Genomics; UpToDate